The industry produces more drugs than ever. Commercial execution remains stubbornly broken. Here is the evidence — using only 2024, 2025, and 2026 data.
Over $300 billion in branded drug sales face patent expiry by 2030 — arriving simultaneously with the most aggressive pricing reforms in pharma history.
% of EMA-approved brands (2021–2024) reimbursed per market. The 5EU reimburses 2.7× more products than the European average. Same regulatory approval. Radically different commercial reality.
The EU Joint Clinical Assessment launched January 2025 for oncology and ATMPs — the most significant HTA reform in a generation. But clinical harmonization is not the same as commercial access.
"What worked in 2020 no longer applies in 2025. Global access planning must become granular."
Most pharma companies have launched digital transformation programs. The results, measured from the HCP side, are sobering.
"The gap between omnichannel ambition and execution is vast — and the HCP is paying for it with wasted time."
Despite heavy investments in CRM, content platforms, and digital activation — the HCP experience has not materially improved. The signal is consistent across 2024 and 2025 research.
HCPs are clear: they want digital content on their terms. But they will not show up for low-value interactions — regardless of channel.
Despite massive investment in measuring sales force effectiveness, the foundational metrics are deeply unflattering — and have not materially improved.
Most pharma companies believe they have an omnichannel strategy. What they actually have is siloed channel activation — without connected data, unified HCP profiles, or feedback loops.
The 2025 Medication Access Report synthesizes 180 qualitative interviews and 777 quantitative surveys. The findings reveal systemic failure — not isolated friction.
PA is not just a bureaucratic friction — it is an active barrier between the prescribing moment and the dispensing reality. Physicians may avoid prescribing newly launched drugs entirely if PA friction is too high.
Pharma invests over $5 billion annually building patient support programs. It then largely fails to tell patients or prescribers that they exist.
These five modes do not operate independently. Each amplifies the others. A launch that underperforms on access will underperform on every downstream metric.
PwC Q4 2025 data signals the first pharma commercial outperformance after years of muted results. Companies breaking through are those integrating access, engagement, and patient support — before day one, not after it.
"Winning companies won't wait for certainty. They will experiment boldly, scale what works, and hardwire adaptability into their DNA."